Hohe Ziele – ACR/EULARRemissionskriterien für die rheumatoide Arthritis

Zusammenfassung

Während seit einigen Jahren klar ist, dass wir harte, messbare Parameter benötigen, um gemeinsam mit unseren RA-Patienten einen optimalen Therapieerfolg zu erarbeiten, haben die neuen ACR/EULAR-Remissionskriterien erstmals ein deutlich erkennbares Ziel gesetzt. Die Latte wurde dabei ziemlich hoch gelegt, weshalb dieses Vorgehen teilweise sogar belächelt wurde. Eine Reihe Arbeiten beweisen aber mittlerweile , dass wir bei vielen Patienten in der Lage sind, dieses Ziel zu erreichen, und dass diese Patienten auf Dauer besser vor den Folgen ihrer Erkrankung geschützt sind. Es lohnt sich, dieses Ziel konsequent im Blick zu behalten und darum zu kämpfen, dass Patienten in Remission kommen und bleiben.

Summary

It has been obvious for years that we need hard, measurable parameters of success in order to reach an optimal therapeutic result together with our RA patients. The new ACR/ EULAR criteria of remission have now defined the goal to be reached. Getting there will not come easily, and, indeed, the criteria have been ridiculed in part, as being out of this world. A number of studies, however, have in between shown that we are indeed able to reach this goal in many patients. Moreover, if it is reached, patients are better protected against the sequelae of their disease. It pays to keep remission in focus and to consequently fight for getting patients into remission and keeping them there.

Schlüsselwörter

Rheumatoide Arthritis - Remission - Krankheitsaktivität - Scores - Usuren

Keywords

Rheumatoid arthritis - remission - disease activity - scores - erosions

• Literatur

• 1 Furst DE, Keystone EC, Braun J. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011; 70 (Suppl. 01) i2-i36.
• 2 Smolen JS, Aletaha D, Bijlsma JW. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637.
• 3 Smolen JS, Landewe R, Breedveld FC. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975.
• 4 Felson DT, Smolen JS, Wells G. et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-586.
• 5 Prevoo ML, van ’t Hof MA, Kuper HH. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
• 6 Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 2011; 63: 3702-3711.
• 7 Smolen JS, Breedveld FC, Schiff MH. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-257.
• 8 Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007; 21: 663-675.
• 9 Iking-Konert C, Aringer M, Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011; 70: 1986-1990.
• 10 Smolen JS, Han C, van der Heijde DM. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68: 823-827.
• 11 Burmester GR, Feist E, Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb reallife study (TAMARA). Ann Rheum Dis 2011; 70: 755-759.
• 12 Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis. 2012 Jun 26. [Epub ahead of print]
• 13 Lee YC, Cui J, Lu B. et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/ EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011; 13: R83.
• 14 Lillegraven S, Prince FH, Shadick NA. et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012; 71: 681-686.